Treatment of intraventricular hemorrhage with tissue plasminogen activator

On average, both the third and fourth ventricles became clear on the third day after hemorrhage; there was one exception, a case of ruptured aneurysm. Five of the six patients showed excellent or good outcome, although two developed delayed hydrocephalus. No infection or rebleeding was observed. Post-haemorrhagic hydrocephalus in infancy. Anatomical study. Biol Neonate. Endogenous fibrinolysis in neonatal cerebrospinal fluid. Eur J Pediatr.

Fibrinolysis in cerebrospinal fluid after intraventricular haemorrhage. Arch Dis Child. Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.

Subacute hydrocephalus after experimental subarachnoid hemorrhage: its prevention by intrathecal fibrinolysis with recombinant tissue plasminogen activator.

Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.

Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: preliminary assessment of efficacy and safety in an open clinical study.

Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. Treatment of intraventricular hemorrhage with tissue plasminogen activator. Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage.

Acta Neurochir Wien ; — Intraventricular recombinant tissue plasminogen activator for lysis of intraventricular haemorrhage. J Neurol Neurosurg Psychiatry. Computed tomography scans were performed 12, 48, and 72 h after administration. Primary outcomes included feasibility enrollment and consent rates , safety assessed by prospectively screening for complications , and rate of intracranial blood clearance measured using sequential IVH, modified Graeb, and SAH sum scores.

Secondary outcomes included angiographic vasospasm, delayed cerebral ischemia, need for ventriculoperitoneal shunting, and 6-month neurological outcomes.